SELUTION SLR Drug Eluting Balloon in De Novo Coronary Lesions in Small Vessels

What is the Purpose of this Study?

The purpose of this study is to determine whether an experimental device called the SELUTION SLR drug eluting balloon is safe and whether it works as effectively as other currently available treatments for patients with de novo lesion (a new blockage or narrowing in a blood vessel that has not been previously treated) of the heart arteries. The study focuses on people who have a partially blocked coronary artery (blood vessel in the heart) that has not previously been treated. The SELUTION SLR can be used for treating patients with narrowing of the heart arteries without leaving behind a permanent metal stent. The device is a balloon that opens up narrowing in blood vessels. The unique feature of the balloon is that the surface of the balloon is coated with a drug called sirolimus, which is released over time. Sirolimus is used to prevent thickening of the blood vessel wall, in addition to preventing the blood vessel from narrowing again after it has been opened by the balloon.

Eligibility

Subjects must meet all of the following clinical criteria to participate in the trial:

Inclusion Criteria:

Subjects must meet all of the following clinical criteria to participate in the trial:
1. Subject is ≥ 18 years (or the minimum legal age as required by local regulations).
2. Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before the procedure or are using a contraceptive device or drug.
3. Subject presents with chronic coronary syndromes \[CCS\] (manifest as documented angina or positive functional testing), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with an indication for PCI and planned intervention.
4. Subject can tolerate dual antiplatelet therapy with aspirin, plus either Clopidogrel, Prasugrel, or Ticagrelor. (Note: For subjects requiring oral anticoagulation, aspirin may be omitted based on investigator discretion).
5. Subject has life expectancy \> 1 year in the opinion of the investigator.
6. Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.
1\. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.
Subject's target lesion(s) must meet all of the following angiographic criteria for the subject to participate in the trial:
1. A single, target lesions that meet criteria can be treated in a single vessel. No non-target lesions can be treated within the target vessel in the index procedure. Non-target lesions within the target vessel can be staged for treatment \> 30 days from the index procedure.
2. Up to two (2) non-target lesions in up to two (2) non-target vessels may be treated, but successful PCI of the non-target lesions must be completed before randomization and treatment of the target lesion.
3. Target lesion is ≤ 36 mm in length.
4. Target lesion has diameter stenosis \> 50% and ≤ 99% with distal flow at least thrombolysis in myocardial infarction (TIMI) 2.
5. Target vessel has RVD of ≥ 2.00 mm and ≤ 2.75 mm \[by visual assessment\].
6. Target lesion is within a native coronary artery or major branch.
7. A target lesion within or near a bifurcation is allowed only if a single vessel (either main vessel or side branch) is to be treated.
8. The identified target lesion has high probability (\> 70%) for successful treatment with approved pre-treatment techniques and DEB alone.

Exclusion Criteria:

Subjects who meet any of the following clinical criteria will be excluded from the trial:
1. Subject with known hypersensitivity or allergy to Sirolimus or other pharmacologic agents required for the procedure.
2. Subject presents with NSTEMI and rising biomarkers, or ongoing chest pain or is hemodynamically instable.
3. Subject with history of ST-elevation myocardial infarction (STEMI) within 30 days of the index procedure.
4. Subject with planned major surgery within 30 days following the index procedure.
5. Subject with planned treatment of lesion involving aorto-ostial location.
6. Subject with planned PCI of a non-target vessel within 30 days following the index procedure.
7. Subject with history (within 6 months prior to index procedure) of New York Heart Association (NYHA) class III or IV heart failure.
8. Subject with history of active peptic ulcer or gastrointestinal bleeding within 6 months of the index procedure or other inability to comply with the recommended duration of dual antiplatelet therapy (DAPT).
9. Subject is pregnant, breast-feeding or a woman of childbearing potential who plans pregnancy up to 1 year following index procedure.
10. Subjects with current documented left ventricular ejection fraction (LVEF) \< 30%.
11. Subject is considered not able to tolerate at least 30 seconds of coronary occlusion for the target lesion treated.
12. Subjects is currently participating in another investigational drug or device study that has not completed primary endpoint follow-up.
13. Subject with definite clinically active COVID-19 infection defined as a positive COVID test within 24 hours of index procedure.
1. Any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device has been placed/used in any part of the body within 3 months prior to the index procedure including non-target lesion(s) treated during the index procedure.
2. Planned intervention with any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device anywhere in the body within 6 months after the index procedure. Note: staged procedures \>30 days after index procedure (Exclusion #6 of the main protocol) are permitted only in the main protocol, and are not permitted in this PK sub-study.
3. The subject is taking or has taken within the last 3 months any limus family medication(s) for any reason.
4. Subject is concurrently enrolled in the main protocol angiographic registry.
5. Subjects who are taking strong CYP3A4 Inhibitors within 14 days before the index procedure or plan to take the strong inhibitors during the study period. Strong inhibitors include: cobicistat; ritonavir; indinavir and ritonavir; itraconazole; ketoconazole; lopinavir and ritonavir; paritaprevir and ritonavir and ombitasvir (and/or dasabuvir); posaconazole; saquinavir and ritonavir; tipranavir and ritonavir; elvitegravir and ritonavir; telithromycin; voriconazole; ceritinib; clarithromycin; idealalisib; nefazodone; nelfinavir.
6. Subjects who are taking strong CYP3A4 Inducers within 14 days before the index procedure or plan to take the strong inducers during the study period. Strong inducers include apalutamide; carbamazepine; enzalutamide; ivosidenib; lumacaftor and ivacaftor; mitotane; phenytoin; rifampin; St. John's wort.
Subject whose target lesion(s) meet any of the following angiographic criteria will be excluded from the trial:
1. Target lesion is totally occluded or has evidence of thrombus.
2. Target lesion is located in the left main or any arterial or venous graft.
3. Target lesion is in a side branch that is "jailed" by a main vessel stent.
4. In stent restenosis

Show less

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

A Prospective Randomized Single-Blind Multicenter Study to Assess the Safety and Effectiveness of the SELUTION SLR 014 PTCA Drug Eluting Balloon in the Treatment of Subjects with De Novo Coronary Lesions in Small Vessels

Study Details

Disease Type/Condition

Other

Principal Investigator

Dohad, Suhail

Age Group

Adult

Phase

N/A

IRB Number

STUDY00004001

ClinicalTrials.gov ID

NCT05946629

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

clinicaltrials@cshs.org